We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · March 30, 2021

Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer
Clin. Cancer Res 2021 Mar 08;[EPub Ahead of Print], JJ Lin, NJ Choudhury, S Yoda, VW Zhu, TW Johnson, R Sakhtemani, I Dagogo-Jack, SR Digumarthy, C Lee, A Do, J Peterson, K Prutisto-Chang, W Malik, H Hubbeling, A Langenbucher, AJ Schoenfeld, CJ Falcon, JS Temel, LV Sequist, BY Yeap, JK Lennerz, AT Shaw, MS Lawrence, SI Ou, AN Hata, A Drilon, JF Gainor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading